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The threat posed by the chromosomally encoded class D -lactamase of Acinetobacter baumannii (OXA-51/66) has been un-
clear, in part because of its relatively low affinity and turnover rate for carbapenems. Several hundred clinical variants of OXA-
51/66 have been reported, many with substitutions of active-site residues. We determined the kinetic properties of OXA-66 and
five clinical variants with respect to a wide variety of -lactam substrates. The five variants displayed enhanced activity against
carbapenems and in some cases against penicillins, late-generation cephalosporins, and the monobactam aztreonam. Molecular
dynamics simulations show that in OXA-66, P130 inhibits the side-chain rotation of I129 and thereby prevents doripenem bind-
ing because of steric clash. A single amino acid substitution at this position (P130Q) in the variant OXA-109 greatly enhances the
mobility of both I129 and a key active-site tryptophan (W222), thereby facilitating carbapenem binding. This expansion of sub-
strate specificity represents a very worrisome development for the efficacy of -lactams against this troublesome pathogen.
Acinetobacter baumannii is a Gram-negative coccobacillus thatis responsible for an increasing number of difficult-to-treat
nosocomial infections (1). This species has been labeled a “serious
threat” by the Centers for Disease Control and Prevention, in large
part because of rising levels of antimicrobial resistance associated
with it. A. baumannii is largely resistant to penicillins, cephalospo-
rins, quinolones, aminoglycosides, and tetracyclines, and the only
remaining sustainable treatment option is the carbapenem class of
-lactams (e.g., imipenem, doripenem, and meropenem). Now,
growing levels of carbapenem resistance portend the potential for
extensively drug-resistant A. baumannii strains that are resistant
to almost all antibiotics (2–4). Carbapenem resistance has been
attributed to the loss of outer membrane permeability upon porin
deletion (5), overexpression of efflux pumps (6), and modifica-
tion of the target transpeptidases (7), but the most notable contri-
bution comes from the expression of -lactamases. A wide variety
of -lactamases from all four classes (A to D) have been shown to
be present in A. baumannii (8), but class D carbapenemases have
received the most attention in recent years (9). Most class D car-
bapenemases are characterized by very high affinity for carbap-
enem substrates, coupled to relatively weak catalytic turnover
rates (10). Five subfamilies of class D carbapenemases have been
identified in A. baumannii, namely, OXA-23, OXA-24/40, OXA-
51, OXA-58, and OXA-143 (1).
The general structural features and mechanism of class D
-lactamases have been elucidated, with high-resolution crystal
structures solved for OXA-1 (11), OXA-10 (12), OXA-23 (13),
OXA-24/40 (14), OXA-46 (15), OXA-48 (16), OXA-51 (17), and
OXA-58 (18) (along with several variants) (13, 19, 20). For most of
these enzymes, structures have been determined with substrates or
inhibitors bound in the active site (21–26). Like class A and class C
-lactamases, members of class D make use of a serine-nucleo-
phile acylation/deacylation double-displacement mechanism to
hydrolyze the -lactam ring (10). Two features are unique to class
D enzymes, however. Their active sites are generally hydrophobic,
with conserved residues such as V130, L168, and W167 (OXA-24
numbering) playing key roles in stabilizing active-site architecture
and substrate binding (25, 27, 28). Second, carboxylation of an
active-site lysine results in the formation of a carbamate general
base that deprotonates the serine nucleophile and the deacylating
water (29).
Surrounding the active site are three loops, sometimes referred
to as the omega loop (12), the P loop (30), and a loop connecting
two -strands (5 and 6 in OXA-48 and 8 and 9 in OXA-51)
(16, 17) (Fig. 1). Many sequence modifications in these loops that
enhance or alter the specificity or hydrolytic efficiency of class D
-lactamases have been characterized. Substitutions at positions
in or near the omega loop of OXA-10 subfamily members give rise
to increased activity against ceftazidime and are thus classified
as extended-spectrum -lactamases (ESBL) (31–33). Structural
analysis of one such substitution revealed an altered omega loop
that opened the active site for the binding of the bulky oxyimino
side chain of ceftazidime (19). A single amino acid duplication
(A220dup) in the 56 loop of OXA-23 (13) alters the structure of
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that loop in a way that allows bulky cephalosporins and the mono-
bactam aztreonam to enter the active site, where they can be hy-
drolyzed. A similar substrate expansion is observed in OXA-23 or
OXA-24 clinical variants with a proline-to-serine substitution in
the same loop (20). The sequence and length of the 56 loop
have been implicated in carbapenem targeting as well, as replace-
ment of the 56 loop from the narrow-spectrum OXA-10 with
the loop from OXA-48 imparts carbapenemase activity to the for-
mer (34). Other investigations into the mechanism by which class
D -lactamases hydrolyze carbapenems have focused on a highly
conserved leucine (L168 in OXA-24/40) and how its side chain
affects the ability of a water molecule to enter the active site and
adopt the correct orientation for efficient deacylation of the car-
bapenem acyl-intermediate (16, 23). Some class D carbapen-
emases (OXA-23, OXA-24/40, and variants) contain a pair of res-
idues (Y112 and M223 in OXA-24/40) that extend across the top
of the active site from the P loop and the 56 loop (13, 14). This
so-called “hydrophobic bridge” gives rise to a tunnel-like active
site and is thought to be responsible for the very high affinity of
these enzymes for doripenem and meropenem (14, 22).
There are 500 unique -lactamase enzymes that are officially
recognized as part of class D, as indicated by their OXA identifi-
cation numbers. Of these, 125 are members of the OXA-51-like
subfamily, a group named after an enzyme that was first isolated
from an Acinetobacter baumannii clinical sample from Argentina
in 1996 (35). In contrast to plasmid-borne carbapenemases such
as OXA-23 and OXA-24, the genes that encode OXA-51 and its
closely related variants are usually chromosomal. This observa-
tion gave rise to the suggestion that OXA-51 may be a ubiquitous,
native carbapenemase of A. baumannii (36). Phylogenetic evi-
dence, however, suggests that OXA-65 or OXA-66 (variants of
OXA-51 with 5 and 6 substitutions, respectively) might be closer
to the ancestral sequence of the subfamily (37). Despite the abun-
dance of variants from clinical A. baumannii isolates, the presence
of an OXA-51-like gene does not always lead to carbapenem re-
sistance. The lack of a resistance phenotype may be caused in part
by generally low levels of OXA-51 expression and weaker binding
affinity for carbapenems than those of OXA-23 and OXA-24/40.
Their potential role in resistance was recognized upon the discov-
ery that promoter-like elements such as ISAba1 could be inserted
in front of the coding sequence to drive overexpression of the
enzyme (38). Additionally, variants with single or multiple substi-
tutions in the OXA-51 or OXA-66 background have been con-
nected to antibiotic resistance phenotypes (39–42) and increased
hydrolytic activity for carbapenems (43).
Our understanding of why OXA-51 has such weak carbapen-
emase activity was greatly enhanced by the elucidation of its struc-
ture by Smith and colleagues (17). While the overall fold of
OXA-51 matches quite closely that of the potent carbapenemases
OXA-23 and OXA-24/40, two key active-site differences help ex-
plain the relatively weak binding of carbapenems to OXA-51.
First, a tryptophan (W222) occupies the position of the methio-
nine of the hydrophobic bridge found in OXA-23 and OXA-24/
40. Instead of forming a bridge across the top of the active site,
however, the indole side chain of W222 projects into the binding
cavity, where it would be expected to clash with the C-1 methyl
group of meropenem or doripenem (Fig. 1). In order for those
drugs to bind, the W222 side chain would need to flip 180° away
from the binding site (17). Second, an active-site isoleucine (I129)
projects its  carbon into the active site, where it would likely clash
with the carbapenem’s hydroxyethyl group. This position is occu-
pied by valine in nearly all other non-OXA-51-like class D -lac-
tamases, and structural studies show a very tight fit between the
valine of those enzymes and bound carbapenem substrates
(21–24).
Because OXA-51-like genes are nearly ubiquitous in A. bau-
mannii, any evolutionary adaptation in this family which in-
creases activity against carbapenems (either binding affinity or
turnover) is a serious threat. In this study, we provide evidence
that these changes are indeed emerging rapidly.
MATERIALS AND METHODS
Site-directed mutagenesis. The gene for OXA-66 (codons 26 to 274) was
purchased from GenScript BioTech Corporation (Piscataway Township,
NJ) and cloned into a pET24a() vector using the NdeI and XhoI restric-
tion sites. Substitutions at sites P130, I129, W222, and P226 were intro-
duced by overlap extension PCR (44) using primers purchased from In-
tegrated DNA Technologies (Coralville, IA) and Phusion High-Fidelity
polymerase (ThermoScientific, Inc.). DNA sequences were confirmed by
Sanger dideoxy sequencing at the University of Michigan Sequencing
Core. Final plasmid preparations were used to transform BL21(DE3)
Escherichia coli cells.
Expression and purification of variant enzymes. Expression and pu-
rification of OXA-66 and all other variants were carried out by methods
identical to those used previously for OXA-24 (20). Each enzyme was
purified to 95% purity using carboxy-methyl cellulose CM23 (What-
man, United Kingdom), concentrated to 1 to 3 mg/ml, snap-frozen in
liquid nitrogen, and stored at 80°C. The concentration of each enzyme
preparation was determined using UV spectroscopy (280 nm) in the pres-
ence of 6 M guanidium HCl, with extinction coefficient values calculated
by the method of Gill and von Hippel (45).
FIG 1 OXA-51 aligned to OXA-24/40/doripenem. The overall main-chain
structure of OXA-51 (blue) matches very closely that of OXA-24/40 (cyan).
The structure of doripenem (cyan, center top) indicates the position of the
active site. Both structures contain three loops surrounding the active site:
the P loop and the 56 loop (89 in OXA-51) contribute large hydrophobic
residues that cap the top of the active site, and the omega loop forms the front
wall.
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Determination of steady-state kinetic parameters. Kinetic assays
were performed by combining enzyme variants with -lactam substrates
in 50 mM NaH2PO4 plus 25 mM NaHCO3, pH 7.4, at room temperature.
Mixtures were placed in quartz cuvettes (path length, 1.0 cm or 0.2 cm),
and absorbance was monitored over time. Changes in absorbance were
converted to velocity using the change in extinction coefficient values
specific for each substrate (ampicillin, ε 	 900 M1 · cm1; dorip-
enem, 297 nm, ε 	 11,460 M1 · cm1; imipenem, 300 nm, ε 	
9,000 M1 · cm1; cefotaxime, 260 nm, ε 	 7,500 M1 · cm1;
ceftriaxone, 255 nm, ε 	 7,800 M1 · cm1; ceftazidime, 260 nm,
ε 	 8,660 M1 · cm1; aztreonam, 320 nm, ε 	 700 M1 · cm1).
For enzyme/substrate combinations that yielded very low Km values, Ks
values were measured by using the substrate as a competitor with ampi-
cillin acting as a reporter, as described previously (20).
Molecular dynamics simulations. OXA-66 and its P130Q variant
(OXA-109) were constructed for two parallel simulations using the
OXA-51 apo structure (residues 38 to 274) (Protein Data Bank [PDB]
accession number 5KZH), MMTSB (46), CHARMM (47) and
CHARMM-GUI (48) script libraries, and the VMD package (49). For the
OXA-66 model, the V48, Q107, P194, and D225 residues of OXA-51
sequence were replaced with A, K, Q, and N residues, respectively, using
an MMTSB mutate script. For OXA-109, the P130 residue was replaced
with glutamine, in addition to the other substitutions. OXA enzymes pos-
sess the sequence motif PASTFK (residues 78 to 83) containing a carbox-
ylated lysine that acts as a general base. Force-field parameters for the
carboxylated lysine are provided in our previous study (20). Both proteins
were solvated with TIP3P (50) water molecules in a cubic box with a
dimension of 74 Å. Potassium and chloride ions were added to neutralize
the net charge of the system and to obtain the concentration of 0.15 M (37
anions and 35 cations). The system size was 41,235 atoms/ions for
OXA-66 and 41,250 atoms/ions for OXA-109. The CHARMM27 protein
force field (47) and the CHARMM, version 37b2, simulation package
were used. Geometries of both systems were optimized using the Steepest
Descent algorithm for 1,000 steps and then using the adopted basis New-
ton-Raphson (ABNR) method (51) until the gradient threshold of 0.01
kcal/mol/Å was achieved. During the minimization and simulations, pe-
riodic boundary conditions were applied, and electrostatic interactions
were calculated with the particle mesh Ewald method (52). A switching
function was applied to calculate the van der Waals interactions with a
nonbonded cutoff of 12 Å. The SHAKE algorithm (53) was used to con-
strain the bond lengths involving hydrogen atoms. After minimization,
the systems were heated gradually from 10 K to 300 K for 60 ps (with a 1-fs
time step) and then simulated under NPT (constant number of atoms,
pressure, and temperature) conditions for 200 ps total (with a 1-fs time
step) to equilibrate the water molecules. Harmonic constraints of 10 kcal/
mol/Å2 were initially placed on all of the proteins’ heavy atoms and were
removed during the last 170 ps of NPT simulations. The unconstrained
systems were then simulated for 100 ps under NVT (constant volume)
with a 1-fs time step, after which the time step was increased to 2 fs. The
initial 10 ns was considered the equilibration period, and the data were
collected over 189.6 ns of each productive trajectory. The C
 root mean
square deviation (RMSD) profiles of core secondary elements for OXA-66
and OXA-109 are shown in Fig. S1 in the supplemental material.
Accession number. The OXA-51 structure has been deposited in PDB
under accession number 5KZH.
RESULTS AND DISCUSSION
In order to observe the patterns of amino acid substitutions that
occur in the subfamily of OXA-51-like proteins, we carried out a
BLAST search of the NCBI protein database using OXA-51 or
OXA-66 as a query sequence. Searches were performed with cut-
offs of 90% query coverage, 90% sequence identity, and the de-
fault BLOSUM62 matrix and were limited to Acinetobacter bau-
mannii and Acinetobacter calcoaceticus. Analysis of the aligned
structures revealed 192 unique sequences that met the criteria
when either sequence was used to search. The alignments revealed
that the highest number of substitutions were located near three
sequence motifs which are highly conserved in class D -lactama-
ses and are known to be in or near the active site (Fig. 1 and 2). The
area containing the sequence motif SAI (residues 127 to 129) re-
vealed that substitutions for I129 (L/V/M) and P130 (S/L/Q/A/
T/R) were very common, along with one sequence that had a
substitution at V131 (I). The omega loop contains the WL motif
(residues 166 and 167), which is unique to class D -lactamases.
This region was dominated by substitutions at L167 (V/Q); but
three variants had substitutions at V168 (M/A), and one had a
variation at W166 (L). The 89 loop (analogous to the 56
loop of OXA-48) showed common substitutions in many unique
sequences, most notably W222 (L/G) and D225 (N). While it is
possible that the prevalence of some of these substitutions in a
large number of unique enzymes represents an early mutation
event that was maintained as other substitutions accumulated, a
phylogenetic analysis by Evans et al. suggests that substitutions at
I129, P130, L167, and D225 have arisen independently several
times (37). Building on our previous work that showed gain-
of-function activity for I129L and L167V (43), we chose to ana-
lyze five new OXA-66 variants: OXA-109 (P130Q), OXA-234
(W222L), OXA-PQ/WL (an unnumbered class D -lactamase
with the double substitution P130Q/W222L [54]), OXA-172
(I129V/W222L), and OXA-173 (I129V/W222L/P226L). The se-
quences of these variants are shown in Fig. 2, with common motifs
and substitutions highlighted.
The OXA-66 coding sequence (codons 26 to 274) was pur-
chased as a synthetic gene in the pET24a expression vector, and
the substitutions described above were introduced by overlap ex-
tension PCR (44). Each variant was expressed and purified using
carboxymethyl cellulose ion exchange chromatography. The ki-
netic parameters kcat and Km for each variant were determined
using UV spectroscopy. A wide variety of -lactam substrates were
used, including the penicillin ampicillin, the carbapenems imi-
penem and doripenem, the cephalosporins cefotaxime, ceftazi-
dime, and ceftriaxone, and the monobactam aztreonam. The kcat
and Km values that we measured for OXA-66 closely match those
for OXA-51 (43), suggesting that the six amino acid differences
between these two proteins (T5A, E36V, V48A, Q107K, P194Q,
and D225N) likely have little effect on the hydrolytic efficacy of the
proteins.
All variants displayed parameters that differed markedly from
those of the parental enzyme OXA-66 although the patterns were
unique for each variant and each class of drug (Table 1). The
substitution of a glutamine for P130 results in an overall increase
of at least 10-fold in kcat/Km values for both doripenem and imi-
penem over the value observed for OXA-66. In the case of imi-
penem, the gain in overall efficiency is derived almost entirely
from a lower Km value, suggesting that the substitution results in a
higher affinity for that drug. For doripenem, a modest decrease in
Km (2.5-fold) was accompanied by an approximately 4-fold in-
crease in kcat, indicating that there may be gains in both affinity
and turnover efficiency. The decrease in Km for doripenem was
enough to put the value below the level at which it can be reliably
quantified using UV spectroscopy, so Ks values were determined
indirectly by competition using ampicillin as a reporter substrate.
The Ks of doripenem (0.56 M) indicated that the P130Q substi-
tution did, in fact, lead to increased affinity for carbapenems of at
least 5-fold. That said, the binding does not appear to be quite as
Variant Class D Carbapenemases with Enhanced Activity
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tight as that observed for OXA-24, OXA-23, or even the I129L
mutation of OXA-51, all of which display Ks values of 0.15 nM
(13, 20, 43). The gains afforded by the P130Q substitution were
largely limited to carbapenems as there was only a slight decrease
in the very high Km for the penicillin ampicillin and no detectable
hydrolytic activity for the advanced-generation cephalosporins
cefotaxime, ceftazidime, and ceftriaxone or for the monobactam
aztreonam.
As noted above, the P130Q substitution has appeared clinically
in combination with other mutations in the active site, most no-
tably W222L. A laboratory mutant (W222M) in the OXA-51
background has been shown to increase affinity and overall hy-
drolytic efficiency against carbapenems (17). The position of
W222 at the rim of the active site, with its bulky indole side chain
projecting into the active site, is predicted to cause steric occlusion
of carbapenem substrates (17). We tested variants containing the
W222L substitution alone (OXA-234) and in combination with
P130Q (OXA-66 PQ/WL). Similar to OXA-51 W222M, OXA-234
displayed lower Km and Ks values for doripenem and imipenem as
well as for the penicillin ampicillin. Unlike the situation with the
P130Q substitution, however, the W222L variant led to slightly
lower kcat values for carbapenem substrates, thereby moderating
the overall gain of hydrolytic efficiency observed. The double sub-
stitution of P130Q and W222L resulted in even lower Ks values for
carbapenems, suggesting that the two substitutions can work to-
gether to improve affinity. Such high carbapenem affinities pre-
cluded us from measuring an exact Km, but even lower limits of the
kcat/Km ratios indicate minimum 6-fold and 12-fold increases for
overall efficiency of doripenem and imipenem hydrolysis, respec-
tively. This suggests that if either of these substitutions appeared
on its own, the addition of the other might confer a selective ad-
vantage against carbapenem therapy.
W222L is also found in combination with I129V in OXA-172,
a variant that was isolated from carbapenem-resistant A. bauman-
nii in Taiwan (39). The I129V substitution in OXA-172 is highly
similar to the previously described I129L variant and is sequen-
tially adjacent to P130. This variant displays carbapenem Ks values
as low as those observed for OXA-23 and OXA-24 (50 nM) and
only modestly reduces kcat values compared to those of wild-type
OXA-66. The OXA-172 (OXA-66 I129V/W222L) Km for ampicil-
lin, however, was unchanged compared to that of OXA-234
(OXA-66 W222L), and all three variants containing W222L
(OXA-234, OXA-66 PQWL, and OXA-172) showed no detectable
turnover of advanced-generation cephalosporins or aztreonam.
Perhaps the most interesting OXA-66 variant we tested was
OXA-173, another enzyme that was first identified in Taiwan.
OXA-173 contains the same two substitutions found in OXA-172
(I129V and W222L) but has the additional substitution P226L.
The proline at this position is highly conserved in class D carbap-
enemases, and substitutions for it have been shown to result in
expanded substrate profiles in both the OXA-23 and OXA-24 sub-
families (20). Our analysis of OXA-173 showed a similar expan-
sion of specificity, with a greatly reduced Km for the penicillin
ampicillin and, for the first time in an OXA-51-like enzyme, hy-
drolytic activity against advanced-generation cephalosporins and
the monobactam aztreonam. Along with these gains, we did not
observe any major loss of carbapenemase activity for OXA-173.
These results indicate that this variant is capable of binding and
FIG 2 Alignment of OXA-66 and eight clinical variants. OXA-66 and several variants containing one, two, or three substitutions were aligned using ClustalW.
The red bar between residues 25 and 26 represents the site of proteolytic digestion for removal of the export sequence. Key active-site residues are highlighted with
blue, and the substitutions are highlighted with green. OXA-PQ/WL is a variant without an OXA number and is the P130Q/W222L double mutant of OXA-66
(NCBI RefSeq number WP_001022759).
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hydrolyzing a breadth of substrate classes that is unusual for class
D -lactamases.
Having demonstrated that all five variants of OXA-66 display
reduced Km/Ks values for a variety of -lactam substrates, we
sought to explain how each substitution might alter the active site.
The mechanism by which an I129V substitution in OXA-66 re-
sults in tighter binding of carbapenems can be easily rationalized.
The potential for a steric clash between the side chain of I129 and
the hydroxyethyl group of carbapenem substrates has been noted
(17, 43). Substitution of a valine for an isoleucine at this position
eliminates the  carbon and its potential hindrance of the hy-
droxyethyl moiety. The homologous position in both OXA-23
TABLE 1 Kinetic parameters of OXA-66 and five variants





Ampicillin 20,000 180 NA
Doripenem 5.4  0.4 2.7 0.052  0.001 0.0096  0.0007
Imipenem 71  1 47 0.69  0.01 0.0097  0.0002
Cefotaxime NAb 0.02 NA
Ceftriaxone NA 0.02 NA
Ceftazidime NA 0.02 NA
Aztreonam NA 0.05 NA
OXA-66 P130Q (OXA-109)
Ampicillin 9,100  1,500 510  30 0.056  0.010
Doripenem 2.0 0.56  0.03 0.20  0.01 0.1
Imipenem 5.9  0.6 3.6  0.6 0.55  0.01 0.093  0.010
Cefotaxime NA 0.02 NA
Ceftriaxone NA 0.02 NA
Ceftazidime NA 0.02 NA
Aztreonam NA 0.05 NA
OXA-66 W222L (OXA-234)
Ampicillin 2,200  200 370  10 0.17  0.01
Doripenem 2.0 0.35  0.05 0.034  0.001 0.017
Imipenem 5.6  0.3 2.7  0.2 0.14  0.01 0.025  0.002
Cefotaxime NA 0.02 NA
Ceftriaxone NA 0.02 NA
Ceftazidime NA 0.02 NA
Aztreonam NA 0.05 NA
OXA-66 P130Q/W222L
Ampicillin 870  90 340  10 0.39  0.04
Doripenem 2.0 0.16  0.02 0.13  0.01 0.065
Imipenem 2.2  0.2 0.54  0.07 0.25  0.01 0.11  0.01
Cefotaxime NA 0.02 NA
Ceftriaxone NA 0.02 NA
Ceftazidime NA 0.02 NA
Aztreonam NA 0.05 NA
OXA-66 I129V/W222L (OXA-172)
Ampicillin 2,400  300 770  50 0.32  0.04
Doripenem 2.0 0.011  0.001 0.022  0.001 0.011
Imipenem 2.0 0.049  0.009 0.14  0.01 0.07
Cefotaxime NA 0.02 NA
Ceftriaxone NA 0.02 NA
Ceftazidime NA 0.02 NA
Aztreonam NA 0.05 NA
OXA-66 I129V/W222L/P226L (OXA-173)
Ampicillin 36  7 130  10 3.6  0.8
Doripenem 2.0 0.020  0.005 0.012  0.001 0.006
Imipenem 2.0 0.041  0.009 0.022  0.002 0.011
Cefotaxime 100  4 0.52  0.01 0.0052  0.0002
Ceftriaxone 5.7  1.0 2.3  0.5 0.055  0.003 0.010  0.002
Ceftazidime 1,000 0.25 NA
Aztreonam 170  10 0.34  0.01 0.0020  0.0001
a Ks values were determined by competition kinetics with ampicillin as a reporter substrate.
b NA, not applicable.
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and OXA-24 is occupied by valine, and both of these enzymes
possess very low Km values for carbapenems. Similarly, the gain-
of-function activities observed for the variants containing W222L
can be rationalized from structural analysis. Smith et al. note that
for a carbapenem to bind in OXA-51, the side-chain indole group
of W222 must flip 180° away from the expected position of
carbapenem binding, and that flip would appear to be energeti-
cally unfavorable (17). The side chain of leucine is much smaller
than that of tryptophan, so the steric clash between doripenem
and the far end of the indole side chain (particularly C1) would
likely be eliminated with the W222L substitution. To illustrate
these potential effects, we prepared a model of OXA-172 (OXA-66
I129V/W222L) and superposed it with a model of OXA-66 and
OXA-24/40 in complex with doripenem (OXA-24/40 K84D/
doripenem) (Fig. 3A). First, we used the mutagenesis function of
PyMol to change OXA-51 (PDB code 4ZDX) to OXA-66 by intro-
ducing five substitutions (E36V, A48V, Q107K, P194Q, and
D225N). We then created OXA-172 by introducing the additional
substitutions I129V and W222L. These two PDB models were
superposed on the structure of OXA-24/40 K84D/doripenem
(PDB code 3PAE) to show how the substitutions potentially affect
the interaction with doripenem. Figure 3A strongly supports the
hypothesis that the I129V and W222L substitutions eliminate the
steric clash with doripenem that would occur with the OXA-66
wild type.
Previous studies involving the P227S substitution of OXA-225
and OXA-160 provide a possible explanation for the greatly ex-
panded specificity provided by the substitution at the structurally
homologous P226 position in OXA-173. No matter what residue
is substituted for P226, the loss of the proline’s rigid side-chain
ring will allow much greater freedom of the  torsion angle. In
OXA-160, this enhanced flexibility allows the 56 loop to adopt
an alternative conformation that makes room for the bulky oxy-
imino side chains of advanced-generation cephalosporins and az-
treonam (20). To illustrate this, we built a model of OXA-173
(OXA-66 I129V/W222L/P226L) by adding the P226L substitution
to the OXA-172 model described above. This model was aligned
with the structure of OXA-160 (OXA-24/40 P227S; PDB code
4X53) in the Coot program (55). The 89 loop of the OXA-173
model was then altered to match the backbone trace of the homol-
ogous loop from OXA-160. To show how a cephalosporin sub-
strate might bind in the active sites of OXA-66 and OXA-173,
these two models were superposed on the structure of OXA-225/
ceftazidime (PDB code 4X55). Figure 3B shows that if the P226L
substitution in OXA-173 has the same effect that P227S has on
OXA-160, the 89 loop will move away from the active site and
create a much larger area for binding. This explains how OXA-173
can bind large cephalosporin substrates, including those with
bulky side chains like ceftazidime.
While simple structural comparisons can explain the effects of
most of the substitutions we tested, the cause of significantly re-
duced carbapenem Km values observed for the P130Q substitution
is not as readily apparent. The fact that this residue is sequentially
adjacent to I129, along with the observation that substitutions at
these two positions never appear in the same variant, suggests that
they may be acting through the same mechanism. We wondered if
the change in flexibility that would accompany the loss of the rigid
proline residue at position 130 may affect the geometric con-
straints of the neighboring I129 and thus relieve the potential
steric clash between that residue and the hydroxyethyl moiety of
carbapenem substrates. To test this, we carried out 200-ns molec-
ular dynamics simulations of fully hydrated OXA-66 wild type
and its P130Q variant (OXA-109). The starting structures of
OXA-66 and OXA-66 P130Q (OXA-109) were prepared by mu-
tation of OXA-51 (PDB code 5KZH) (17).
In order to relieve the steric clash with carbapenems, the side
chain of isoleucine would need to rotate in a way that would move
its  carbon away from the predicted location of the drug’s hy-
droxyethyl group. Isoleucine can adopt three rotamers, gauche
(), gauche (), and trans, with gauche () being the form that
is observed in the wild-type OXA-51 structure (Fig. 4). Through-
out the 190 ns of productive trajectory of wild-type OXA-66, the
side chain of I129 adopts the gauche () rotamer 96% of the time,
maintaining its  carbon in a position unfavorable to carbapenem
binding. The majority of the remaining 4% of the time is repre-
sented by a single continuous period in which I129 adopts the
trans rotamer, with the  carbon rotated toward the side chain of
L167. The introduction of a P130Q substitution into the OXA-66
background alters the I129 rotamer distribution strikingly (Fig.
4). The time spent in the carbapenem-unfavorable gauche ()
rotamer is reduced to 35%, while the trans form rises to 42% and
the gauche () is 24%. It should be noted that the trans form is
analogous to the rotamer form of V130 observed in the carbap-
enem-bound form of OXA-24/40 (22). Thus, even in the absence
of bound carbapenem, the P130Q substitution induces a large
increase in the population of the I129 rotamer that is most com-
patible with binding that class of drug.
We considered two possible explanations for this effect. First,
the loss of the rigid ring structure connecting the side chain of
FIG 3 Models of OXA-172 and OXA-173. To help explain the potential struc-
tural effects of the substitutions that resulted in enhancement of hydrolytic
activities, we constructed models of variants that contained those substitu-
tions. (A) Model of OXA-66 I129V/W222L (OXA-172; magenta) superposed
with a model of OXA-66 wild type (blue) and OXA-24/40/doripenem (PDB
code 3PAE) (cyan; ligand only). (B) Model of OXA-66 I129V/W222L/P226L
(OXA-173; yellow) superposed with a model of OXA-66 wild type (blue) and
OXA-225/ceftazidime (PDB code 4X55) (salmon; ligand only). dori, dorip-
enem; ceftaz, ceftazidime.
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P130 to its backbone nitrogen may facilitate an increase in main-
chain flexibility and thereby give the side chain of I129 more free-
dom to overcome the energetic barrier to rotation. Arguing
against this, the trajectories reveal that in both OXA-66 and OXA-
109, the I129 side chain is able to sample all three states. The
difference was thus not in the ability of I129 to access the other
rotamers but, rather, in the longer duration during which it pop-
ulated the trans and gauche () positions in OXA-109. Addition-
ally, the main-chain torsion angles for both positions 129 and 130
are essentially unchanged from OXA-66 to OXA-109 (Table 2).
Observation of the behavior of I129 during the OXA-66 trajectory
reveals a second possibility. The rotation of I129 away from its
favored gauche () position requires one of its two  carbons to
come into close contact with the  carbon of the neighboring
P130. To switch to the trans rotamer, I129L C2 must approach
uncomfortably close to P130 C (3.5 Å). Rotating the other way
to the gauche () rotamer results in a similar steric clash for 1.
Thus, the gauche () position for I129 is the most thermodynam-
ically stable position because the alternative rotamers are crowded
by the  carbon of the neighboring P130. If this hypothesis is true,
substitution of any other residue (not just glutamine) for proline
at position 130 would result in relief of these steric influences on
rotamer selection, more readily allowing the forms favorable to
carbapenem binding. In support of this, analysis of position 130 in
OXA-51/66 clinical variants reveals examples of every amino acid
substitution that can be achieved with a single nucleotide switch
(alanine, serine, leucine, glutamine, threonine, and arginine).
This explanation is further supported by the increased binding
affinity for carbapenems that is observed when an I129L substitu-
tion is introduced into OXA-51 (20). The lack of -branching in
the leucine would be predicted to allow its rotation away from the
hydroxyethyl without the unfavorable interactions with P130. But
if it is the -branched structure of I129 that induces an energetic
cost upon rotation to the carbapenem-favorable trans rotamer,
why does the similarly -branched valine present in OXA-23 and
OXA-24 not result in weaker carbapenem binding? The answer
may lie in the sole difference between valine and isoleucine, that is,
the  carbon of the latter. In the case of OXA-23 with meropenem
bound, the valine maintains the gauche () rotamer and there-
fore does not clash with P130. Its lack of a  carbon, however,
presents much less steric challenge to the meropenem hydroxy-
ethyl (23). In OXA-24/40 with doripenem bound, V130 rotates
into the trans rotamer where one of its  carbons is forced into
close proximity with the  carbon of the neighboring proline (22).
The absence of the terminal  carbon on the valine in this case may
allow more room for that side chain to move toward leucine 168
(on the omega loop) and possibly reduce any clash with the neigh-
boring proline (P131). Further examination of the packing of
bound carbapenem, I129, P130, and L167 by more extensive mo-
lecular dynamics or structural techniques may identify other sub-
tle differences between OXA-66 and OXA-24/40 that could influ-
ence the suitability of a -branched residue in the trans rotamer at
residue 129.
We examined the trajectories to see if the P130Q substitution
had any influence on W222, whose indole ring presents the other
major steric challenge for carbapenem binding. We saw unexpect-
edly large effects of the P130Q substitution on the rotational fluc-
tuations of the two side-chain torsion angles (1 and 2) for W222
(data not shown). We illustrate this effect by plotting the distance
FIG 4 Rotamer position of I129 in OXA-66 and OXA-109. The 1 torsion angle for I129 was plotted as a function of time for OXA-66 (blue) and OXA-109
(green). Rotamers (approximate structures shown at right) were binned as follows: gauche (), 120°  1 0°; gauche (), 0°  1 120°; trans, 180° 
1  120° and 120°  1 180°. For purposes of clarity, 1 values between 120° and 180° were shifted to the top of the graph by adding 360°.
TABLE 2 Average main-chain torsion angles for residues at position
129 and 130
Enzyme  angle (°)  angle (°)
OXA-66 I129 57.3  7.9 44.8  5.8
OXA-109 I129 65.2  9.3 37.4  8.7
OXA-66 P130 58.9  10.6 32.1  9.8
OXA-109 Q130 61.6  7.5 37.0  7.9
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between the carbon at the far end of the indole ring (carbon C2)
and the expected position of the C-1 methyl carbon of doripenem
over the productive period of the simulation trajectory (Fig. 5).
The position of doripenem was modeled through alignment of
core secondary element C
 atoms of OXA-66 or OXA-109 to the
OXA-24/40/doripenem structure (PDB code 3PAE). As Fig. 5
shows, this distance remains close to 2 Å throughout the OXA-66
trajectory (1.96  1.01 Å), indicating that W222 projects into the
active site in a position incompatible with doripenem binding for
most of the simulation time. For the OXA-109 trajectory, how-
ever, the side chain of W222 regularly flips out of the active site,
resulting in much greater average distances (6.13  2.61 Å). Thus,
the presence of a single substitution (P130Q) has effects on both
I129 and W222 that are predicted to increase the binding affinity
of carbapenem substrates. A representative frame of OXA-109 in
which these two residues simultaneously adopt positions that are
favorable to doripenem binding is shown superimposed on an
OXA-66 frame showing these residues in the position they adopt
in the OXA-51 crystal structure (Fig. 6).
Given that the P130Q substitution is on the opposite side of the
active site from W222, how could the former induce such a large
conformational effect on the latter? As Smith et al. point out, the
orientation of W222 is dependent on the compensating stabilizing
forces for its alternative positions (directed toward or away from
the binding site) (17). In the crystal structure they present, the
indole ring directly contacts the  carbon of I129 (3.8 Å and 4.0 Å
to the C2 and C2 carbons of W222, respectively). The rotation of
I129 away from the gauche () rotamer would eliminate these
stabilizing contacts and might thus increase W222 side-chain mo-
bility. W222 contacts a large number of residues, and thus more
extensive networks of interactions may be involved.
The results we present here show that substitutions in the ac-
tive site of OXA-66 lead to higher catalytic efficacy for the hydro-
lysis of carbapenems and, in some cases, other classes of -lactam
antibiotics. The ease with which single substitutions yield catalytic
gains raises an important question: if the presence of an isoleucine
at position 129 and a tryptophan at position 222 depresses activity
so much, why do most OXA-51/66 enzymes have them? One pos-
sible answer is that these two residues are part of a hydrophobic
packing unit (along with L167, L110, F111, and W220) that sig-
nificantly stabilizes the overall structure. Further studies that in-
vestigate the effect of these substitutions on protein stability may
reveal that there is some trade-off between stability and activity
similar to what has been observed for other -lactamases (20, 56,
57). The fact that these substitutions have appeared in clinical A.
FIG 5 Comparison of the distance between the side chain of W222 and the expected position of doripenem in OXA-66 and OXA-109. The distance between the
C-1 methyl carbon of the pyrroline ring of doripenem and the C2 of W222 was measured for each frame of the OXA-66 trajectory (blue) and the OXA-109
trajectory (green). To estimate the position of doripenem in the active sites of OXA-66 and OXA-109, the structures were aligned with the structure of
OXA-24/40/doripenem (PDB code 3PAE). Representative snapshots of the position of W222 pointing away from the binding site (OXA-109; green) or toward
the binding site (OXA-66; blue) are shown at right.
FIG 6 Stereo view of the superposition of frames from the molecular dynam-
ics simulation of OXA-66 (blue) and OXA-109 (green) with acyl-doripenem
from the crystal structure of OXA-24/40 (PDB 3PAE) (cyan; OXA-24/40 pro-
tein not shown). In OXA-66, I129 and W222 predominantly occupy positions
that would be expected to clash extensively with the hydroxyethyl (I129) and
pyrroline C-1 methyl (W222) groups of doripenem. The introduction of the
P130Q substitution in OXA-109 leads to alternative conformations of both
residues that greatly alleviate the steric clash.
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baumannii isolates so often and have many times been shown to
increase carbapenem resistance in those isolates suggests that any
such trade-offs do not diminish the adaptive potential that they
provide.
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